Skip to main content

Huff Curtis W's Form 4 filing

Comera Life Sciences Holdings, Inc.CMRA · filed Jan 3, 2024

Accession no.
0000950170-24-001385
Filed
Jan 3, 2024, 8:09 PM ET
Trade date
Dec 29, 2023
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 2 derivative transactions. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Huff Curtis WCIK 000125012710% Owner
Freebird Partners LPCIK 000195523110% Owner
Freebird Investments LLCCIK 000197140610% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 29, 2023Common Stock, par value $0.0001 per sharePPurchaseAcquired+2,453,636$0.055+$134,949.982,453,636Direct
Dec 29, 2023Common Stock, par value $0.0001 per sharePPurchaseAcquired+4,907,272–F2,F3–7,362,005Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions").

Referenced by the price of 1 transaction in Table II.

F3

(Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company.

Referenced by the price of 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)